HumanFirst reported adoption by 22 of the top 25 pharmaceutical companies for digital measure selection. Enterprise teams use Atlas to shorten technology diligence and standardize endpoint choices.
The company raised about 15M dollars in total funding through its Series A. That capital base supported catalog growth and pharma partnerships before the ICON acquisition.
ICON acquired HumanFirst in early 2024 to extend its digital health technology offering. ICON company history records the acquisition of the cloud-based life sciences technology company that year.
HumanFirst continues to operate as a subsidiary brand under ICON with its Atlas platform. The combination pairs ICON trial execution scale with HumanFirst curated digital endpoint catalog.
The Atlas platform curates validated digital biomarkers, electronic clinical outcome assessments, and connected sensor technologies. Research teams browse thousands of measures mapped to clinical conditions and trial needs.
Atlas supports sponsors selecting digital endpoints, comparing devices, and deploying measures into decentralized studies. The catalog approach reduces diligence time when designing technology-enabled trial protocols.
